` RXRX (Recursion Pharmaceuticals Inc) vs S&P 500 Comparison - Alpha Spread

RXRX
vs
S&P 500

Over the past 12 months, RXRX has underperformed S&P 500, delivering a return of -46% compared to the S&P 500's 10% growth.

Stocks Performance
RXRX vs S&P 500

Loading
RXRX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
RXRX vs S&P 500

Performance Gap Between RXRX and GSPC
HIDDEN
Show

Performance By Year
RXRX vs S&P 500

Loading
RXRX
S&P 500
Add Stock

Competitors Performance
Recursion Pharmaceuticals Inc vs Peers

S&P 500
RXRX
ABBV
AMGN
GILD
VRTX
Add Stock

Recursion Pharmaceuticals Inc
Glance View

Market Cap
2B USD
Industry
Biotechnology

In the bustling landscape of biotech innovation, Recursion Pharmaceuticals Inc. carves a distinctive niche by marrying the worlds of biology and advanced computational techniques. Founded in 2013, this Salt Lake City-based company embarked on a mission to decode the complex tapestry of disease biology through the lens of data science and machine learning. Recursion's approach centers around its unique platform that integrates automated experimental biology with artificial intelligence to map and navigate the intricate pathways of human cellular biology. By harnessing volumes of data from high-throughput biological experiments, they aim to unearth novel insights into a multitude of diseases, particularly those that have historically evaded effective therapeutic intervention. At the heart of Recursion's business model is its ability to discover potential drug candidates rapidly and efficiently, turning traditional pharmaceutical development on its head. The company generates revenue through strategic partnerships with pharmaceutical giants, leveraging its platform to accelerate drug discovery and development processes. Collaborations often involve sharing the risk and reward of drug discovery, with Recursion providing the technological backbone to sift through vast datasets and identify promising therapeutic compounds. Additionally, Recursion invests in its pipeline of proprietary drug candidates, targeting rare genetic diseases and areas of significant unmet medical need. By aligning cutting-edge technology with the complexities of human biology, Recursion Pharmaceuticals positions itself at the forefront of transforming how diseases are understood and how new treatments are developed.

RXRX Intrinsic Value
HIDDEN
Show
Back to Top